Physician profile
Tiffany Lu
NPI 1437998119
$4,511.72
in general payments reported to CMS, 2019-2025
9 companies · $3,404 in 2025
The $3,404 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,108 · 2025: $3,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,192 · Travel and Lodging: $1,105 · Entertainment: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,192.04 |
| Travel and Lodging | $1,105.30 |
| Entertainment | $214.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valley Contax, INC. | $2,202.49 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $853.40 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $465.48 | 2024-2025 | Miebo, Xiidra, Zenlens |
| Biotissue Holdings INC. | $385.04 | 2024 | |
| Dompe US, INC. | $241.62 | 2024-2025 | Oxervate |
| Alcon Vision LLC | $240.48 | 2024-2025 | Precision 7, Rocklatan |
| Oyster Point Pharma, INC. | $50.71 | 2024-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $45.50 | 2025 | |
| Harrow Eye, LLC | $27.00 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.